lucar-e9d
Cell therapyexperimental
Clinical trial activity
1 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 5, 2025 (NCT07093411)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07093411 | Early Phase 1 (Phase 1) | Aug 5, 2025 | Anhui Medical University, Government of China, Jiao Tong University, Wenzhou Medical University, Xuzhou Medical University, Zhengzhou University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Wenzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Xuzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2025 |
6 organizations
Page 1 / 1